Home Intervjuer ExpreS2ion CEO comments ongoing rights issue

ExpreS2ion CEO comments ongoing rights issue

Bent U. Frandsen, CEO ExpreS2ion Biotech talks about the development and the rights issue

ExpreS2ion CEO comments ongoing rights issue

5 april, 2023

ExpreS2ion Biotechnologies has a broad portfolio of vaccine candidates based on its ExpreS2 platform. Right now, the company is eagerly awaiting top-line results from the phase III study with its Covid-19 vaccine. Meanwhile the cancer vaccine candidate ES2B-C001 is advancing towards the clinic. The company is currently raising 102 MSEK in a rights issue. BioStock invited CEO Bent U. Frandsen to the studio to find out more about the technology, the ongoing development and the current capital raise.

See the interview with ExpreS2ion Biotechnologies CEO Bent U. Frandsen below.

The invitation to persons concerned to subscribe for units in ExpreS2ion Biotechnologies will only take place through the prospectus published on 27 March 2023. The prospectus has been approved and registered by the Financial Supervisory Authority and published on https://expres2ionbio.com/.

Artikelns innehåll är sponsrat av det aktuella bolaget som förekommer i texten. BioStock tillhandahåller inte investeringsrådgivning, förmedlar inga investeringsorder och tar inget ansvar för agerande och/eller eventuell förlust eller skada av något slag som grundar sig på användandet av innehåll som publicerats på BioStock.se. Varje investeringsbeslut fattas istället självständigt av den enskilde investeraren.

Prenumerera på BioStocks nyhetsbrev